Rhythm Pharmaceuticals
Rhythm Pharmaceuticals' revenue rose 45.8% to $190 million in fiscal 2025. Its operating margin was −101.2%, up from −204.0% a year earlier. Free cash flow was −$117 million. The diluted share count rose 6.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Rhythm Pharmaceuticals does
Rhythm Pharmaceuticals sells medicines for rare diseases that cause intense, constant hunger and severe obesity. These conditions trace to faults in the melanocortin-4 receptor (MC4R) pathway, a signaling system in the brain that helps control hunger and how the body uses energy.
Its one marketed product is IMCIVREE (setmelanotide). It is sold in the United States, the European Union, the United Kingdom, Canada and some other places for certain rare genetic obesity diseases, including Bardet-Biedl syndrome. The company makes money by selling this drug. It says it expects to launch IMCIVREE in the United States in 2026 for acquired hypothalamic obesity, which is weight gain caused by injury to part of the brain, if regulators approve it.
Rhythm is also testing two earlier-stage drugs in the same family: bivamelagon, taken by mouth, and RM-718, designed to be given once a week by injection. It holds worldwide rights to IMCIVREE and global rights to these two. It had 414 employees on February 1, 2026, including some in 11 countries outside North America.
Its biggest risks, as it describes them
- It has a limited history selling drugs and has not yet earned significant revenue from them.
- It may need to raise more funding, which may not be available on acceptable terms.
- Its revenue interest financing agreement with Healthcare Royalty Partners could limit its cash and its choices.
- Results from earlier trials may not predict later ones, and early data it announces may change.
- The number of patients with each rare disease it targets is small and not precisely known.
Income statement
Rhythm Pharmaceuticals lost money in fiscal 2025: a net loss of $196 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 295 | 333 | 276 | 321 | 389 |
| Debt incl. finance leases | — | — | 106 | 110 | 108 |
| Net debt (negative means net cash) | — | — | −170 | −211 | −281 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.6x | 5.0x | 0.8x |
| Interest coverage | — | −34.5x | −13.3x | −12.9x | −9.3x |
| Current ratio | 7.1x | 8.9x | 5.6x | 3.2x | 4.4x |
| Quick ratio | 7.1x | 8.8x | 5.4x | 3.1x | 4.2x |
Cash flow
Projections
Project Rhythm Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Rhythm Pharmaceuticals shares on the open market, and 9 insiders sold $36.4 million, $35.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | David P MeekerPresident and CEO, Director | Sold plan | 50,000 | $102.67 | $5.1 million | Form 4 |
| Aug 31, 2026 | Hunter C SmithChief Financial Officer | Sold plan | 62,774 | $105.46 | $6.6 million | Form 4 |
| Aug 13, 2026 | Jennifer Kayden LeeEVP, Head of North America | Sold plan | 75,834 | $117.38 | $8.9 million | Form 4 |
| Aug 13, 2026 | Alastair GarfieldChief Scientific Officer | Sold plan | 7,763 | $117.57 | $912,697 | Form 4 |
| Aug 13, 2026 | Joseph ShulmanChief Technical Officer | Sold plan | 5,079 | $119.75 | $608,210 | Form 4 |
| Aug 12, 2026 | Yann MazabraudEVP, Head of International | Sold plan | 57,000 | $116.15 | $6.6 million | Form 4 |
| Jun 22, 2026 | Lynn A. TetraultDirector | Sold plan | 37,000 | $100.32 | $3.7 million | Form 4 |
| May 15, 2026 | Christopher Paul GermanCorporate Controller & CAO | Sold | 4,643 | $92.21 | $428,131 | Form 4 |
| Mar 4, 2026 | Christopher Paul GermanCorporate Controller & CAO | Sold | 5,614 | $89.56 | $502,790 | Form 4 |
| Feb 19, 2026 | Hunter C SmithChief Financial Officer | Sold plan | 4,385 | $101.26 | $444,009 | Form 4 |
| Feb 17, 2026 | Hunter C SmithChief Financial Officer | Sold plan | 3,569 | $101.38 | $361,813 | Form 4 |
| Feb 12, 2026 | Hunter C SmithChief Financial Officer | Sold plan | 1,592 | $98.23 | $156,378 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 6 of 9 |
| Rule of 40 | 51.6% | −19.4% | −15.6% |
| Altman Z'' | −6.41 | −9.72 | −6.24 |
| Accruals ratio | −13.6% | −40.5% | −18.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | 3 of 9 | 6 of 9 |
Compare
Put Rhythm Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
| Syndax Pharmaceuticals | FY25 | 627.8% | −158.4% | −187.5% | — | — | — | Compare |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
| Liquidia | FY25 | 1,031.2% | −32.5% | −25.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 77 | 130 | 190 |
| Revenue growth | — | — | — | — | — | — | 649.5% | 227.6% | 68.1% | 45.8% |
| Gross profit | — | — | — | — | — | 3 | 22 | 68 | 117 | 170 |
| Research and development | 20 | 23 | 50 | 109 | 90 | 104 | 109 | 135 | 238 | 167 |
| Operating income | −26 | −32 | −78 | −146 | −137 | −170 | −179 | −184 | −266 | −192 |
| Net income | −26 | −34 | −74 | −141 | −134 | −70 | −181 | −185 | −261 | −196 |
| Diluted EPS (US$) | −2.85 | −2.83 | −2.39 | −3.86 | −3.04 | −1.40 | −3.47 | −3.20 | −4.34 | −3.11 |
| Diluted shares (millions) | 10 | 13 | 31 | 36 | 44 | 50 | 52 | 58 | 61 | 65 |
| Cash flow | ||||||||||
| Cash from operations | −23 | −30 | −62 | −123 | −122 | −146 | −173 | −136 | −114 | −116 |
| Capital expenditure | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free cash flow | −24 | −30 | −63 | −126 | −122 | −146 | −174 | −136 | −114 | −117 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 6 | 12 | 18 | 21 | 20 | 33 | 40 | 67 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 148 | 252 | 292 | 173 | 295 | 333 | 276 | 321 | 389 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 106 | 110 | 108 |
| Total assets | 12 | 152 | 260 | 308 | 187 | 330 | 382 | 333 | 392 | 480 |
| Total liabilities | 5 | 7 | 14 | 28 | 20 | 45 | 118 | 163 | 228 | 210 |
| Shareholders' equity | −33 | 145 | 246 | 281 | 166 | 284 | 264 | 170 | 22 | 139 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% |
| Operating margin | — | — | — | — | — | −5,391.9% | −757.9% | −238.1% | −204.0% | −101.2% |
| Net margin | — | — | — | — | — | −2,207.1% | −766.2% | −238.5% | −200.3% | −103.6% |
| Free cash flow margin | — | — | — | — | — | −4,642.9% | −734.9% | −175.9% | −87.5% | −61.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | −85.4% | 51.6% | −19.4% | −15.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −60.1% | −37.9% | −53.4% | −59.9% | −30.9% | −66.0% | −85.1% | −272.2% | −244.4% |
| Return on assets | — | −41.1% | −36.0% | −49.5% | −54.1% | −26.9% | −50.9% | −51.6% | −71.9% | −45.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |